LUXTURNA (voretigene neparvovec-rzyl)
OPHTHALMIC - RETINAL ENZYME REPLACEMENT · BIALLELIC RPE65 MUTATION-ASSOCIATED RETINAL DYSTROPHY
SPARK THERAPEUT
Drug class
Ophthalmic - Retinal Enzyme Replacement
The phrase "Ophthalmic - Retinal Enzyme Replacement" does not designate a formal FDA-established therapeutic class, but rather describes a specialized therapeutic concept investigated for localized metabolic eye disorders. Read more about Ophthalmic - Retinal Enzyme Replacement
2 drugs in this class 2 manufacturers
Drugs in Ophthalmic - Retinal Enzyme Replacement
ENCELTO (revakinagene taroretcel-lwey)
OPHTHALMIC - RETINAL ENZYME REPLACEMENT · IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2
NEUROTECH PHARM
Filter & compare in the drug finder →
Opens the drug finder with Ophthalmic - Retinal Enzyme Replacement preselected. Add indication or manufacturer filters there.
The phrase "Ophthalmic - Retinal Enzyme Replacement" does not designate a formal FDA-established therapeutic class, but rather describes a specialized therapeutic concept investigated for localized metabolic eye disorders.
In clinical research and compendia, this approach involves the direct ocular delivery—most commonly via intravitreal administration—of an active recombinant enzyme directly to retinal tissue.
Its principal mechanism is to catabolize toxic intracellular storage material that bypasses systemic or intracerebroventricular therapies, thereby mitigating progressive neuroretinal degeneration.
Its primary application under clinical investigation is the prevention of blindness in lysosomal storage disorders affecting the visual system, notably neuronal ceroid lipofuscinosis type 2 (CLN2/Batten disease) associated with tripeptidyl peptidase 1 deficiency.
-
araceagainstblindness.org
The phrase "Ophthalmic - Retinal Enzyme Replacement" does not designate a formal FDA-established therapeutic class, but rather describes a specialized therapeutic concept investigated for localized metabolic eye disorders
-
nih.gov
The phrase "Ophthalmic - Retinal Enzyme Replacement" does not designate a formal FDA-established therapeutic class, but rather describes a specialized therapeutic concept investigated for localized metabolic eye disorders In clinical research and compendia, this approach involves the direct ocular delivery—most commonly via intravitreal administration—of an active recombinant enzyme directly to retinal tissue Its principal mechanism is to catabolize toxic intracellular storage material that bypa...
-
nih.gov
In clinical research and compendia, this approach involves the direct ocular delivery—most commonly via intravitreal administration—of an active recombinant enzyme directly to retinal tissue
-
nih.gov
Its principal mechanism is to catabolize toxic intracellular storage material that bypasses systemic or intracerebroventricular therapies, thereby mitigating progressive neuroretinal degeneration
-
nih.gov
Its primary application under clinical investigation is the prevention of blindness in lysosomal storage disorders affecting the visual system, notably neuronal ceroid lipofuscinosis type 2 (CLN2/Batten disease) associated with tripeptidyl peptidase 1 deficiency
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.